Potential drug interactions with melatonin.

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• Melatonin, a hormone regulating sleep-wake cycles, is metabolized primarily via 6-hydroxylation, mainly by cytochrome P450 1A2 (CYP1A2).
• Concurrent drug administration may alter melatonin's metabolism and efficacy.
• Understanding potential drug-melatonin interactions is crucial for patient safety.

Purpose of the Study:

• To investigate potential in vitro interactions between melatonin and commonly co-administered drugs.
• To assess the suitability of rat hepatic preparations as a model for human melatonin metabolism studies.

Main Methods:

• Human and rat hepatic post-mitochondrial preparations were used for in vitro studies.
• Preparations were incubated with melatonin or 6-hydroxymelatonin in the presence of various drug concentrations.
• The production of 6-sulphatoxymelatonin was quantified using radioimmunoassay.

Main Results:

• Only 5-methoxypsoralen, a potent CYP1A2 inhibitor, significantly impaired melatonin 6-hydroxylation at pharmacologically relevant concentrations.
• Diazepam, tamoxifen, and acetaminophen did not affect melatonin's metabolic conversion to 6-sulphatoxymelatonin at therapeutic concentrations.
• 17-Ethinylestradiol inhibited 6-hydroxymelatonin sulphation, but this is unlikely to cause clinical interactions.
• Significant species differences were observed, suggesting rats are not ideal surrogates for human melatonin metabolism studies.

Conclusions:

• Clinical interactions between melatonin and most tested drugs are unlikely.
• 5-Methoxypsoralen poses a potential risk for drug interactions with melatonin.
• Rat models may not accurately reflect human drug-melatonin metabolic interactions.